Podcasts about Epilepsy syndromes

What Infantile Epilepsy Syndromes are, potential disease-modifying treatments, steroids, and research - all fabulously explained by epileptologist & neuroscientist Stéphane Auvin! ------------------------------------------ More about Stéphane:

Hear why genetic epilepsy syndromes (largely found in young children) have been reclassified - and not without deep thought or consideration! With world-renowned peadiatric consultant neurologist & researcher Sameer Zuberi.---More about Sameer: https://www.torierobinson.com/epilepsy-sparks-insights/sameer-zuberi-02---Glossary:There are many terms used in this recording which you can find in the Epilepsy Sparks Glossary: https://www.epilepsysparks.com/glossary---Follow Torie on:- Twitter: https://twitter.com/torierobinson10- LinkedIn: https://www.linkedin.com/torierobinson- Instagram: https://www.instagram.com/torierobinson10- Facebook: https://www.facebook.com/TorieRobinsonSpeaker- Check out the website: https://www.torierobinson.com

Il 14 febbraio si celebra la Giornata internazionale dell'epilessia (International Epilepsy Day), evento mondiale che ogni anno si rinnova per promuovere la consapevolezza di una malattia neurologica cronica che colpisce molte persone. Vi proponiamo uno stralcio dell'intervista realizzata a Giovanni Barbieri, per parlare dei tanti stereotipi, delle ansie e dei pregiudizi dal punto di vista in prima persona di vive questa condizione. Una condizione che porta ad una ‘disabilità' invisibile, su cui ancora si sa troppo poco.COS'È L'EPILESSIA?“La parola epilessia deriva dal verbo greco e′πιλαµβa′νειν (epilambanein) che significa “essere sopraffatti, colti di sorpresa”. L'epilessia è una malattia caratterizzata dalla persistente predisposizione dell'encefalo a generare crisi epilettiche. Quest'ultime sono manifestazioni cliniche molto variegate, che insorgono improvvisamente, hanno breve durata (da pochi secondi a ~2-3 minuti) e sono determinate da impulsi elettrici abnormi di uno o più gruppi di neuroni “ipereccitabili”.” Fonte: Società Italiana di Neurologia“L'età pediatrica è particolarmente colpita da questa malattia, risultando una delle fasce di età più in cui questa condizione si manifesta con più frequenza.Si parla di epilessia, ma sarebbe più corretto parlare di epilessie in quanto alcune forme esordiscono precocemente, già nei primi mesi di vita (e possono associarsi ad altre manifestazioni di un disturbo dello sviluppo del sistema nervoso) altre in differenti età dello sviluppo. Alcune forme possono guarire, altre sono croniche ma controllate dai farmaci, altre sono farmaco resitenti (circa il 30%).Le cause possono essere genetiche, strutturali, infettive, metaboliche, autoimmuni.Lo studio dell'eziologia (cioè la causa) rappresenta un momento importante per la diagnosi e il trattamento dell'epilessia, a tutte le età ma particolarmente in quella pediatrica quando per la famiglia la conoscenza della causa di malattia assume significato non solo ai fini della condivisione delle scelte terapeutiche e della comprensione delle ipotesi prognostiche ma anche all'interno del delicato equilibrio familiare di vissuti e preoccupazioni rispetto ad una condizione di per sé già poco conosciuta e piuttosto temuta o addirittura scongiurata.L'approccio alle epilessie in età pediatrica ha implicazioni particolari. Un elemento di grande rilievo risiede nella eterogeneità e nella varietà delle forme sindromiche, le quali hanno diversa gravità e diverse cause. Le cause dell'epilessia e l'età d'esordio sono i fattori principali che influenzano la prognosi dell'epilessia.Negli ultimi anni lo studio delle cause dell'epilessia ha ricevuto un grande impulso dagli avanzamenti tecnici nel campo della genetica e dalle conoscenze da essi prodotti. Una causa genetica determina o influenza l'andamento nel più del 70% delle sindromi epilettiche (Dunn P, Albury CL, Maksemous N, et al. Next Generation Sequencing Methods for Diagnosis of Epilepsy Syndromes. Front Genet 2018;9:20).Il gruppo di epilessie in cui è più probabile identificare una causa genetica comprende i bambini con epilessia a esordio precoce, che non risponde ai farmaci, che ha un ritardo dello sviluppo, una disabilità intellettiva, a volte dei dismorfismi associati. Il riconoscimento ed inquadramento diagnostico è fondamentale per un approccio di precisione che abbia l'obiettivo di trattare le crisi e che al tempo stesso si curi di tutto il percorso di sviluppo del bambino, prevenendo se possibile o curando le comorbidità.È per questi motivi che nell'ambito specialistico della Neuropsichiatria Infantile possono essere affrontate in modo approfondito e al tempo stesso completo, le epilessie ad esordio infantile.” Fonte: IRCCSQUANTO È DIFFUSA?L'e. colpisce l'1% della popolazione: in Italia ne sono portatori oltre 500.000 individui e ogni anno si verificano oltre 25.000 nuovi casi. Il termine sta a indicare una modalità di reagire del sistema nervoso centrale ai più svariati stimoli, che si traduce clinicamente nella comparsa di crisi di cui si conoscono oltre 40 tipi diversi. La crisi epilettica è dovuta a un'improvvisa alterazione dello stato di equilibrio delle membrane neuronali che, attraverso un meccanismo di depolarizzazione, determina una scarica improvvisa e ipersincrona di una popolazione di neuroni. Il fenomeno si traduce clinicamente in una particolare forma di attacco epilettico, legata alla sede e al numero di neuroni coinvolti dalla scarica anomala, nonché al grado di maturazione cerebrale del soggetto che la presenta. COME SI PRESENTANO LE CRISI EPILETTICHE?“La diagnosi di e. si basa su dati clinici ricavati dalle informazioni che il paziente è in grado di fornire sulle proprie crisi, e soprattutto da ciò che possono riferire testimoni oculari opportunamente interrogati. Può essere di sussidio diagnostico l'elettroencefalogramma (EEG), che consente di avere informazioni sulla funzionalità elettrica di diverse aree neuronali e di registrare le scariche abnormi responsabili delle crisi. Queste possono essere circoscritte, oppure generalizzate, scatenate da particolari manovre, quali l'iperventilazione o la stimolazione luminosa intermittente, e possono essere correlate con l'evento critico (EEG critico), oppure costituire un elemento del tracciato di base (EEG intercritico). Recentemente ha acquistato molta importanza il video-EEG, un metodo che permette la contemporanea registrazione su video del segnale elettroencefalografico e della fenomenologia clinica presentata dal paziente; l'analisi simultanea dei dati acquisiti rende possibile studiare la crisi epilettica nella sua globalità. L'attuale classificazione delle crisi epilettiche e delle sindromi a esse correlate individua tre categorie principali: le e. idiopatiche, dipendenti dall'età, la cui causa non è una lesione, ma la presenza di una predisposizione genetica; le e. criptogenetiche, in cui non è dimostrabile una causa (che comunque deve essere esistita) e le e. sintomatiche, in cui è documentabile una lesione responsabile delle crisi.”Fonte: TreccaniIMPORTANTE: UNA CRISI EPILETTICA NON IMPLICA LA DIAGNOSI DI EPILESSIA“Avere una crisi epilettica non significa necessariamente essere affetti da epilessia. Molte situazioni possono, infatti, determinare la comparsa di crisi epilettiche isolate, destinate a non ripetersi più spontaneamente (in assenza cioè di quella situazione che le ha generate): l'innalzamento della febbre nei bambini piccoli (fino a 5 anni: “convulsioni febbrili”), l'abuso o l'astinenza da alcool, l'uso di droghe, disturbi metabolici (ad esempio riduzione brusca dei livelli di glicemia, etc..).La diagnosi di epilessia si basa sulla raccolta completa della storia clinica spesso con l'ausilio dei familiari o di chi ha assistito alle crisi. In seguito, si passa all'esecuzione dell'elettroencefalogramma (EEG) e di indagini quali TAC e/o risonanza magnetica. Altri accertamenti (esami genetici, PET, SPECT) vengono utilizzati in casi selezionati.” Fonte: Società Italiana di Neurologia

Monisha Goyal MD discusses pediatric epilepsy syndromes. She examines the difference between benign & catastrophic epilepsy syndromes and she shares the role of genetic testing in for these conditions. She offers the latest treatment options available and when it is important to refer to the experts at UAB Medicine.

Go online to PeerView.com/RGT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Seizure management in patients with Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), or tuberous sclerosis complex (TSC) can be extremely challenging, since current antiepileptic drugs, even in combination, are usually insufficient for preventing recurrent severe seizures associated with these treatment-resistant epilepsies. A prescription pharmaceutical formulation of highly purified cannabidiol (CBD) is approved for the treatment of seizures in patients 1 year of age or older with DS, LGS, and TSC, making it the first plant-derived cannabis-based medicine approved by the FDA. In this activity, based on a recent live webcast, neurology and pharmacy expert panelists will interpret the latest clinical evidence shaping optimal use of FDA-approved CBD for the management of severe treatment-resistant epilepsies and will provide their perspectives on recent regulatory decisions that impact patient and provider access to this therapy. Upon completion of this activity, participants will be able to: Describe the rationale for and potential benefits of cannabidiol (CBD) for patients with seizure disorders and other medical conditions, Summarize the characteristics, efficacy/safety profiles, and current indications of oral CBD in treatment-resistant epilepsies, Review the impact of recent legal and regulatory decisions on the availability, distribution, and payer coverage of an FDA-approved oral CBD formulation, Integrate cannabidiol into treatment plans for appropriate patients with treatment-resistant epilepsies in managed care settings, Educate patients, caregivers, and other members of the managed care team about the distinction between pharmaceutical-quality and dispensary-derived cannabinoid products.

Go online to PeerView.com/RGT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Seizure management in patients with Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), or tuberous sclerosis complex (TSC) can be extremely challenging, since current antiepileptic drugs, even in combination, are usually insufficient for preventing recurrent severe seizures associated with these treatment-resistant epilepsies. A prescription pharmaceutical formulation of highly purified cannabidiol (CBD) is approved for the treatment of seizures in patients 1 year of age or older with DS, LGS, and TSC, making it the first plant-derived cannabis-based medicine approved by the FDA. In this activity, based on a recent live webcast, neurology and pharmacy expert panelists will interpret the latest clinical evidence shaping optimal use of FDA-approved CBD for the management of severe treatment-resistant epilepsies and will provide their perspectives on recent regulatory decisions that impact patient and provider access to this therapy. Upon completion of this activity, participants will be able to: Describe the rationale for and potential benefits of cannabidiol (CBD) for patients with seizure disorders and other medical conditions, Summarize the characteristics, efficacy/safety profiles, and current indications of oral CBD in treatment-resistant epilepsies, Review the impact of recent legal and regulatory decisions on the availability, distribution, and payer coverage of an FDA-approved oral CBD formulation, Integrate cannabidiol into treatment plans for appropriate patients with treatment-resistant epilepsies in managed care settings, Educate patients, caregivers, and other members of the managed care team about the distinction between pharmaceutical-quality and dispensary-derived cannabinoid products.

Go online to PeerView.com/RGT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Seizure management in patients with Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), or tuberous sclerosis complex (TSC) can be extremely challenging, since current antiepileptic drugs, even in combination, are usually insufficient for preventing recurrent severe seizures associated with these treatment-resistant epilepsies. A prescription pharmaceutical formulation of highly purified cannabidiol (CBD) is approved for the treatment of seizures in patients 1 year of age or older with DS, LGS, and TSC, making it the first plant-derived cannabis-based medicine approved by the FDA. In this activity, based on a recent live webcast, neurology and pharmacy expert panelists will interpret the latest clinical evidence shaping optimal use of FDA-approved CBD for the management of severe treatment-resistant epilepsies and will provide their perspectives on recent regulatory decisions that impact patient and provider access to this therapy. Upon completion of this activity, participants will be able to: Describe the rationale for and potential benefits of cannabidiol (CBD) for patients with seizure disorders and other medical conditions, Summarize the characteristics, efficacy/safety profiles, and current indications of oral CBD in treatment-resistant epilepsies, Review the impact of recent legal and regulatory decisions on the availability, distribution, and payer coverage of an FDA-approved oral CBD formulation, Integrate cannabidiol into treatment plans for appropriate patients with treatment-resistant epilepsies in managed care settings, Educate patients, caregivers, and other members of the managed care team about the distinction between pharmaceutical-quality and dispensary-derived cannabinoid products.

Go online to PeerView.com/RGT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Seizure management in patients with Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), or tuberous sclerosis complex (TSC) can be extremely challenging, since current antiepileptic drugs, even in combination, are usually insufficient for preventing recurrent severe seizures associated with these treatment-resistant epilepsies. A prescription pharmaceutical formulation of highly purified cannabidiol (CBD) is approved for the treatment of seizures in patients 1 year of age or older with DS, LGS, and TSC, making it the first plant-derived cannabis-based medicine approved by the FDA. In this activity, based on a recent live webcast, neurology and pharmacy expert panelists will interpret the latest clinical evidence shaping optimal use of FDA-approved CBD for the management of severe treatment-resistant epilepsies and will provide their perspectives on recent regulatory decisions that impact patient and provider access to this therapy. Upon completion of this activity, participants will be able to: Describe the rationale for and potential benefits of cannabidiol (CBD) for patients with seizure disorders and other medical conditions, Summarize the characteristics, efficacy/safety profiles, and current indications of oral CBD in treatment-resistant epilepsies, Review the impact of recent legal and regulatory decisions on the availability, distribution, and payer coverage of an FDA-approved oral CBD formulation, Integrate cannabidiol into treatment plans for appropriate patients with treatment-resistant epilepsies in managed care settings, Educate patients, caregivers, and other members of the managed care team about the distinction between pharmaceutical-quality and dispensary-derived cannabinoid products.

Go online to PeerView.com/RGT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Seizure management in patients with Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), or tuberous sclerosis complex (TSC) can be extremely challenging, since current antiepileptic drugs, even in combination, are usually insufficient for preventing recurrent severe seizures associated with these treatment-resistant epilepsies. A prescription pharmaceutical formulation of highly purified cannabidiol (CBD) is approved for the treatment of seizures in patients 1 year of age or older with DS, LGS, and TSC, making it the first plant-derived cannabis-based medicine approved by the FDA. In this activity, based on a recent live webcast, neurology and pharmacy expert panelists will interpret the latest clinical evidence shaping optimal use of FDA-approved CBD for the management of severe treatment-resistant epilepsies and will provide their perspectives on recent regulatory decisions that impact patient and provider access to this therapy. Upon completion of this activity, participants will be able to: Describe the rationale for and potential benefits of cannabidiol (CBD) for patients with seizure disorders and other medical conditions, Summarize the characteristics, efficacy/safety profiles, and current indications of oral CBD in treatment-resistant epilepsies, Review the impact of recent legal and regulatory decisions on the availability, distribution, and payer coverage of an FDA-approved oral CBD formulation, Integrate cannabidiol into treatment plans for appropriate patients with treatment-resistant epilepsies in managed care settings, Educate patients, caregivers, and other members of the managed care team about the distinction between pharmaceutical-quality and dispensary-derived cannabinoid products.

Go online to PeerView.com/RGT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Seizure management in patients with Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), or tuberous sclerosis complex (TSC) can be extremely challenging, since current antiepileptic drugs, even in combination, are usually insufficient for preventing recurrent severe seizures associated with these treatment-resistant epilepsies. A prescription pharmaceutical formulation of highly purified cannabidiol (CBD) is approved for the treatment of seizures in patients 1 year of age or older with DS, LGS, and TSC, making it the first plant-derived cannabis-based medicine approved by the FDA. In this activity, based on a recent live webcast, neurology and pharmacy expert panelists will interpret the latest clinical evidence shaping optimal use of FDA-approved CBD for the management of severe treatment-resistant epilepsies and will provide their perspectives on recent regulatory decisions that impact patient and provider access to this therapy. Upon completion of this activity, participants will be able to: Describe the rationale for and potential benefits of cannabidiol (CBD) for patients with seizure disorders and other medical conditions, Summarize the characteristics, efficacy/safety profiles, and current indications of oral CBD in treatment-resistant epilepsies, Review the impact of recent legal and regulatory decisions on the availability, distribution, and payer coverage of an FDA-approved oral CBD formulation, Integrate cannabidiol into treatment plans for appropriate patients with treatment-resistant epilepsies in managed care settings, Educate patients, caregivers, and other members of the managed care team about the distinction between pharmaceutical-quality and dispensary-derived cannabinoid products.

Go online to PeerView.com/RGT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Seizure management in patients with Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), or tuberous sclerosis complex (TSC) can be extremely challenging, since current antiepileptic drugs, even in combination, are usually insufficient for preventing recurrent severe seizures associated with these treatment-resistant epilepsies. A prescription pharmaceutical formulation of highly purified cannabidiol (CBD) is approved for the treatment of seizures in patients 1 year of age or older with DS, LGS, and TSC, making it the first plant-derived cannabis-based medicine approved by the FDA. In this activity, based on a recent live webcast, neurology and pharmacy expert panelists will interpret the latest clinical evidence shaping optimal use of FDA-approved CBD for the management of severe treatment-resistant epilepsies and will provide their perspectives on recent regulatory decisions that impact patient and provider access to this therapy. Upon completion of this activity, participants will be able to: Describe the rationale for and potential benefits of cannabidiol (CBD) for patients with seizure disorders and other medical conditions, Summarize the characteristics, efficacy/safety profiles, and current indications of oral CBD in treatment-resistant epilepsies, Review the impact of recent legal and regulatory decisions on the availability, distribution, and payer coverage of an FDA-approved oral CBD formulation, Integrate cannabidiol into treatment plans for appropriate patients with treatment-resistant epilepsies in managed care settings, Educate patients, caregivers, and other members of the managed care team about the distinction between pharmaceutical-quality and dispensary-derived cannabinoid products.

Go online to PeerView.com/RGT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Seizure management in patients with Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), or tuberous sclerosis complex (TSC) can be extremely challenging, since current antiepileptic drugs, even in combination, are usually insufficient for preventing recurrent severe seizures associated with these treatment-resistant epilepsies. A prescription pharmaceutical formulation of highly purified cannabidiol (CBD) is approved for the treatment of seizures in patients 1 year of age or older with DS, LGS, and TSC, making it the first plant-derived cannabis-based medicine approved by the FDA. In this activity, based on a recent live webcast, neurology and pharmacy expert panelists will interpret the latest clinical evidence shaping optimal use of FDA-approved CBD for the management of severe treatment-resistant epilepsies and will provide their perspectives on recent regulatory decisions that impact patient and provider access to this therapy. Upon completion of this activity, participants will be able to: Describe the rationale for and potential benefits of cannabidiol (CBD) for patients with seizure disorders and other medical conditions, Summarize the characteristics, efficacy/safety profiles, and current indications of oral CBD in treatment-resistant epilepsies, Review the impact of recent legal and regulatory decisions on the availability, distribution, and payer coverage of an FDA-approved oral CBD formulation, Integrate cannabidiol into treatment plans for appropriate patients with treatment-resistant epilepsies in managed care settings, Educate patients, caregivers, and other members of the managed care team about the distinction between pharmaceutical-quality and dispensary-derived cannabinoid products.

Think you might have what it takes to join the extraordinary league of gentle-people against epilepsy? Well you’ll need some training first. Come join Davor and Rahul for a shake-down of the epilepsy world. P.S. I tried my best to … Continue reading →

Joseph Sullivan, MD, Neurology and Pediatrics, UCSF. Series: "Developmental Disabilities Update" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 34673]

Joseph Sullivan, MD, Neurology and Pediatrics, UCSF. Series: "Developmental Disabilities Update" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 34673]

Joseph Sullivan, MD, Neurology and Pediatrics, UCSF. Series: "Developmental Disabilities Update" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 34673]

Joseph Sullivan, MD, Neurology and Pediatrics, UCSF. Series: "Developmental Disabilities Update" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 34673]

Joseph Sullivan, MD, Neurology and Pediatrics, UCSF. Series: "Developmental Disabilities Update" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 34673]

Joseph Sullivan, MD, Neurology and Pediatrics, UCSF. Series: "Developmental Disabilities Update" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 34673]

Joseph Sullivan, MD, Neurology and Pediatrics, UCSF. Series: "Developmental Disabilities Update" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 34673]

Joseph Sullivan, MD, Neurology and Pediatrics, UCSF. Series: "Developmental Disabilities Update" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 34673]